Security key
74346N701
Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (PPCB)
CUSIP: 74346N701
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 128,890
- Total 13F value
- $69,467
- Share change
- +16,784
- SEC-reported price per share
- $0.54
- Number of holders
- 4
- Value change
- -$39,571
- Number of buys
- 3
- Number of sells
- 2
- Shares outstanding
- 12,703,253
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
4
Top holders
4
PPCB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Propanc Biopharma, Inc. SEC filings
Propanc Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74346N701
Recent filing periods:
Ownership snapshot
Top reported holders of PPCB - Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Marex Group Ltd
Disclosed value leader
Marex Group Ltd
Comparable rows
3/6
Latest evidence
30 Sep 2025
13F
3/4/5
Lead comparable stake: 0.55%
3 rows are not safely comparable across share classes.
Quick read
Marex Group Ltd leads the comparable SEC ownership view at 0.55%.
3 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Marex Group Ltd's linked filing trail.
Comparable ownership
Top 3
Marex Group Ltd
0.55%
Virtu Financial LLC
0.33%
MORGAN STANLEY
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Marex Group Ltd |
13F
Company
|
0.55%
|
$119,729
70,429 shares
|
— | 30 Sep 2025 |
| Virtu Financial LLC |
13F
Company
|
0.33%
|
$71,000
41,677 shares
|
— | 30 Sep 2025 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$2
1 shares
|
— | 30 Sep 2025 |
| Josef Zelinger |
3/4/5
Director
|
—
mixed-class rows
|
—
15,002,805 shares
mixed-class rows
|
— | 05 Jul 2023 |
| James Andrew Nathanielsz |
3/4/5
CEO/CFO, Director
|
—
class O/S missing
|
—
8,728,004 shares
|
— | 17 Aug 2021 |
| Julian Norman Kenyon |
3/4/5
Chief Scientific Officer, Director
|
—
class O/S missing
|
—
3,420,005 shares
|
— | 17 Aug 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
128,890
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
3
Q4 2025 holders
4
Holder diff
1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend